<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079999</url>
  </required_header>
  <id_info>
    <org_study_id>17-030</org_study_id>
    <nct_id>NCT03079999</nct_id>
  </id_info>
  <brief_title>Study of Aspirin in Patients With Vestibular Schwannoma</brief_title>
  <official_title>Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II prospective, randomized, double-blind, longitudinal study evaluating&#xD;
      whether the administration of aspirin can delay or slow tumor growth and maintain or improve&#xD;
      hearing in VS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II prospective, randomized, double-blind, longitudinal study evaluating&#xD;
      whether the administration of aspirin can delay or slow tumor growth and maintain or improve&#xD;
      hearing in VS patients. In the Randomized Treatment Phase, patients aged 12 years or older&#xD;
      with VSs will be identified and recruited into one of two randomized groups who receive&#xD;
      either 1) 325 mg aspirin twice daily (81 mg aspirin twice daily for pediatric patients &lt;50&#xD;
      kg); or 2) a placebo. Patients will stay on aspirin/placebo as long as there is no more than&#xD;
      20% increase in VS volume. At tumor progression, patients will enter the Open Label Follow Up&#xD;
      Phase. Patients who progress on placebo will be given the option to receive unblinded aspirin&#xD;
      and will be followed until further progression, receiving a definitive treatment (e.g,&#xD;
      surgery or radiation), or 42 months post-baseline, whichever occurs first. Patients who&#xD;
      progress on aspirin (either blinded or unblinded) will be taken off study drug and followed&#xD;
      until they receive a definitive treatment (e.g., surgery or radiation) or reach 42 months&#xD;
      post-baseline, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In the Randomized Treatment Phase, patients aged 12 years or older with VSs will be identified and recruited into one of two randomized groups who receive either 1) 325 mg aspirin twice daily (81 mg aspirin twice daily for pediatric patients &lt;50 kg); or 2) a placebo. Patients will stay on aspirin/placebo as long as there is no more than 20% increase in VS volume. At tumor progression, patients will enter the Open Label Follow Up Phase. Patients who progress on placebo will receive unblinded aspirin. Patients who progress on aspirin (either blinded or unblinded) will be taken off study drug and followed. All patients will be followed for at least 3.5 years after randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Progression, or around 3.5 years</time_frame>
    <description>Progression Free Survival (PFS) is the length of time from start of study treatment to tumor growth of more than 20%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Vestibular Schwannoma</condition>
  <condition>Acoustic Neuroma</condition>
  <condition>Neurofibromatosis 2</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on the experimental arm will receive blinded aspirin. Pediatric subjects who weigh less than 110 lbs will take 81mg aspirin twice a day. All other subjects will take 325mg aspirin twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients on the placebo arm will receive blinded placebo and take it twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Twice daily aspirin</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Zoprin</other_name>
    <other_name>Durlaza</other_name>
    <other_name>Bayer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Twice daily placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic).&#xD;
&#xD;
          -  Ageâ‰¥12 years.&#xD;
&#xD;
          -  Ability to provide informed consent.Pediatric patients must provide assent in addition&#xD;
             to their parents'/guardians' consent. Adult patients who cannot consent for themselves&#xD;
             will not be eligible to participate in this study.&#xD;
&#xD;
          -  Ability to swallow tablets.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to perform volumetric measurements of vestibular schwannoma(s).&#xD;
&#xD;
          -  Inability to tolerate MRI with contrast.&#xD;
&#xD;
          -  Daily use of aspirin within the last two months. Occasional use of aspirin for pain&#xD;
             relief is not exclusionary.&#xD;
&#xD;
          -  Known allergy to aspirin.&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of aspirin.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients with serious medical illnesses (e.g. severe asthma) that in the option of the&#xD;
             investigator could prevent participation in the trial.&#xD;
&#xD;
          -  Active bleeding diathesis.&#xD;
&#xD;
          -  Hydrocephalus from brainstem compression.&#xD;
&#xD;
          -  Febrile illness or flu-like illness in children and adolescents less than 18 years of&#xD;
             age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantina Stankovic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D. Bradley Welling, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alyssa Brown</last_name>
    <phone>617-573-3632</phone>
    <email>alyssa_brown@meei.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>D. Bradley Welling, MD, PhD</last_name>
    <phone>6175733632</phone>
    <email>Brad_Welling@MEEI.HARVARD.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Otolaryngology/HNS</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Homer Abaya</last_name>
      <phone>650-723-7697</phone>
      <email>habaya@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Konstantina Stankovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Constanza Pelusso</last_name>
      <email>CPelusso@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Fred Telischi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Burke</last_name>
      <email>diane-burke@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Marlan Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Brown</last_name>
      <email>alyssa_brown@meei.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bradley Welling, MD, PhD</last_name>
      <phone>617-573-3632</phone>
      <email>Brad_Welling@MEEI.HARVARD.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>D. Bradley Welling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Tuchscherer, CCRC</last_name>
      <phone>507-538-6582</phone>
      <email>Tuchscherer.Amy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Neff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Esplin</last_name>
      <email>jordan.esplin@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Gorton, CCRP</last_name>
      <email>Kimberly.Gorton@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neil Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Gurgel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Dr. Bradley Welling</investigator_full_name>
    <investigator_title>Walter Augustus Lecompte Distinguished Professor Harvard Department of Otolaryngology-Head and Neck Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
    <mesh_term>Neurofibromatosis 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

